Questcor Can't Kick Securities Fraud Case

Law360, Los Angeles (October 2, 2013, 4:15 PM EDT) -- A California federal judge on Tuesday kept alive most of a securities fraud class action against Questcor Pharmaceuticals Inc., finding investors had sufficiently alleged the company had misrepresented the clinical support for its Acthar drug and the stability of insurance reimbursement rates.

U.S. District Dolly M. Gee said Questcor shareholders could proceed with fraud claims based on three out of four categories of false and misleading statements alleged in a consolidated class action. The proposed class says Questcor lied about the efficacy of Acthar, which accounts...
To view the full article, register now.




Case Information

Case Title

In re Questcor Securities Litigation

Case Number



California Central

Nature of Suit



Dolly M. Gee

Date Filed

September 26, 2012

Law Firms


Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.